Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

@article{Kappos2014AtaciceptIM,
  title={Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial},
  author={Ludwig Kappos and H. P. Hartung and Mark Steven Freedman and Alexey Boyko and Ernst Wilhelm Rad{\"u} and Daniel D. Mikol and Marc Lamarine and Yann Hyvert and Ulrich Freudensprung and Thomas Plitz and Johan van Beek},
  journal={The Lancet Neurology},
  year={2014},
  volume={13},
  pages={353-363}
}

Figures and Tables from this paper

Multiple sclerosis: Atacicept increases relapse rates in multiple sclerosis
  • E. Bible
  • Biology, Medicine
    Nature Reviews Neurology
  • 2014
TLDR
In patients with MS, depletion of B-cell populations through targeting of the CD20 receptor with monoclonal antibodies such as rituximab or ocreluzimab has been shown to reduce both the frequency of relapses and the numbers of inflammatory lesions on MRI.
ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis
Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
TLDR
The topline results of two phase-III randomized clinical trials demonstrate superiority of ocrelizumab over interferon beta in RRMS patients with regards to clinical and paraclinical outcome parameters.
Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders
TLDR
Treatment with atacicept does not seem to be effective and the authors should consider and highlight the complex nature of testing immunomodulatory treatments in MS; whilst B cells are a valid target, the net effect of any B cell-targeting drug is highly complex and can be unpredictable.
Telitacicept Following Plasma Exchange in the Treatment of Subjects With Recurrent NMOSD: Study Protocol for a Single-Center, Single-Arm, Open-Label Study
TLDR
The safety and effectiveness of telitacicept following plasma exchange regarding the time to recurrence in neuromyelitis optica spectrum disorder (NMOSD) for the first time is explored.
Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme
TLDR
An integrated safety analysis of pooled safety data from all 17 clinical studies to date found that pharmacodynamic effects of atacicept were not associated with increased infection rates and treatment-emergent adverse event rates were generally higher than placebo, but no consistent association was found between atACicept dose and specific TEAEs or mortality.
Ocrelizumab for the treatment of multiple sclerosis
TLDR
Ocrelizumab is the first anti-CD20 monoclonal antibody approved for RRMS and the first treatment approved for PPMS, and the long-term effect and safety profile need to be evaluated in extension of clinical trials and in real-world studies.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial.
TLDR
The primary end point (ACR20-CRP response) was not met despite significant biologic effects of atacicept that were consistent with its proposed mechanism of action.
Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial.
TLDR
The results suggest that decreasing the expression of RF may not be sufficient to induce clinical improvement in RA, and clear biologic activity consistent with the proposed mechanism of action was observed.
Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study.
TLDR
The results demonstrated that the biologic activity of atacicept was consistent with its mechanism of action, and was well tolerated both systemically and locally.
TNF neutralization in MS
TLDR
Lenercept failed to be beneficial, but insight into the role of TNF in MS exacerbations was gained.
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
TLDR
A single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks and provides evidence of B-cell involvement in the pathophysiology of relapsing-remitting multiple sclerosis.
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.
TLDR
Biologic activity of atacicept was demonstrated by dose-dependent reductions in immunoglobulin levels and in mature and total B cell numbers and demonstrated biologic activity consistent with the proposed mechanism of action.
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis
TLDR
Rituximab add-on therapy was effective based upon blinded radiologic endpoints in this phase II study and b-cell–modulating therapy remains a potential option for treatment of patients with relapsing MS with an inadequate response to standard injectable therapies.
Trends in annualized relapse rates in relapsing–remitting multiple sclerosis and consequences for clinical trial design
TLDR
Adaptive strategies such as BSSR designs are recommended for consideration in the planning of future trials in RRMS after a systematic review of placebo-controlled, randomized trials and by modelling the ARR over time.
Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers
TLDR
Results showed that single subcutaneous doses of atacicept were well tolerated in healthy volunteers, demonstrated non-linear PK and were biologically active, according to IgM levels.
...
1
2
3
4
...